
Live from SupplySide Global 2026, Nutritional Outlook’s Nicholas Jacobus speaks with Michael Anthonavage, VP of innovation at Vitaquest International, about the company’s 2027 consumer trends forecast and how it’s shaping supplement formulation.
Enzymotec Ltd. has signed a long term deal to supply krill oil to Lupin Ltd. (Mumbai, India), a leading pharmaceutical company focusing on non-steroidal anti-inflammatory drugs, bacterial infections, and cardiovascular disease.
Enzymotec Ltd. (Migdal HaEmek, Israel) has signed a long term deal to supply krill oil to Lupin Ltd. (Mumbai, India), a leading pharmaceutical company focusing on non-steroidal anti-inflammatory drugs, bacterial infections, and cardiovascular disease.
Lupin is the world’s fifth largest pharmaceutical company, based on subscriptions, says Enzymotec.
A Krill Oil+ product will launch later this year in Indian markets.






